Company / SG&A Expense
Centessa Pharmaceuticals plc SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$50.5M
FY2025
5-year range
$42.9M / $55.2M
FY2021-FY2025
Trend
-0.7%
vs FY2024
Sector context
#159 of 213
Health Care
What the data says
Centessa Pharmaceuticals plc's sg&a expense of $50M is lower than 75% of companies in the Health Care sector (FY2025). SG&A Expense has declined for 3 consecutive years, from $55M in FY2022 to $50M in FY2025.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of +113.5%.
Improved from $54M to $50M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- +113.5%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 213This company $50.5M Sector average $722.3M
▼
-93.0% below sector average
Key checks
Key Insights
- Centessa Pharmaceuticals plc's sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +113.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.7% year-over-year.
- Ranks #159 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.5M | -0.7% |
| FY2024 | $50.8M | -5.4% |
| FY2023 | $53.7M | -2.7% |
| FY2022 | $55.2M | +28.7% |
| FY2021 | $42.9M | +3665.4% |
| FY2020 | $1.1M | +44.2% |
| FY2019 | $790.0K | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026